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Background: Unlike bone tissue, articular cartilage regeneration has not been very successful and has many
challenges ahead. We have previously developed injectable hydrogels using photopolymerizable chitosan (MeGC)
that supported growth of chondrocytes. In this study, we demonstrate a biofunctional hydrogel for specific use in
cartilage regeneration by conjugating transforming growth factor-β1 (TGF-β1), a well-documented chondrogenic
factor, to MeGC hydrogels impregnating type II collagen (Col II), one of the major cartilaginous extracellular matrix
(ECM) components.
Results: TGF-β1 was delivered from MeGC hydrogels in a controlled manner with reduced burst release by
chemically conjugating the protein to MeGC. The hydrogel system did not compromise viability of encapsulated
human synovium-derived mesenchymal stem cells (hSMSCs). Col II impregnation and TGF-β1 delivery significantly
enhanced cellular aggregation and deposition of cartilaginous ECM by the encapsulated cells, compared with pure
MeGC hydrogels.
Conclusions: This study demonstrates successful engineering of a biofunctional hydrogel with a specific
microenvironment tailored to promote chondrogenesis. This hydrogel system can provide promising efficacious
therapeutics in the treatment of cartilage defects.
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Chondrogenic differentiationBackground
More than 70 million adults in the United States suffer
from articular cartilage injuries caused mainly by arth-
ritis. An estimated economic burden to arthritis-related
disability would be $100 billion by 2020 as elderly popu-
lation continues to grow [1]. Although autologous chondro-
cyte implantation (ACI) is clinically available for articular
cartilage injuries, successful regeneration of damaged ar-
ticular cartilage remains a great challenge due to the limi-
tations (e.g. multiple surgical procedures, in vitro cell
expansion) associated with ACI [2-5]. Consequently, tissue* Correspondence: leemin@ucla.edu
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unless otherwise stated.engineering approaches have been utilized for articular
cartilage regeneration [6,7]. However, unlike bone, cartil-
age regeneration using tissue engineering strategies has
not been successful due to unfavorable selection of appro-
priate cell sources, scaffolds and/or biomolecules to pre-
cisely restore structure and function of the elegantly
organized tissue [8,9].
Recently, in an effort to remove harsh conditions and
chemicals used in scaffold fabrication, our laboratory
have developed the chitosan-based hydrogel system by
utilizing mild visible blue light (VBL) and riboflavin
(vitamin B2) as a light source and an initiator, respect-
ively, instead of popular choices of UV light and harmful
photoinitiators [10,11]. As a result, the delivery system
bio-degraded to match growth rates of cartilage regener-
ation and removed harsh chemicals while maintainingis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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crucial for cartilage regeneration during chondrogenesis
of mesenchymal stem cells (MSCs) [12]. Yet, systematic
tissue engineering approaches is still required for suc-
cessful cartilage repair.
Among numerous biomolecules for cartilage repair,
transforming growth factor-β1 (TGF-β1) has been ex-
plored to enhance chondrogenic differentiation of cartil-
age forming cells as well as biomechanical properties of
neocartilage [13,14]. However, therapeutic efficacy of
TGF-β1 is affected by delivery kinetics due to its intrin-
sic protein instability and rapid enzymatic degradation
in vivo requiring a high therapeutic dose. The high dose
requirement can cause adverse side effects such as fi-
brotic disorders and unwanted osteophyte formation in
the synovium [15,16]. Sulfated polysaccharides such as
heparin have been shown to form stable complexations
with TGF-β1, which maintain the biological activity and
can sustain the protein release [17-20]. Recent studies
have used this affinity binding of heparin for the con-
trolled delivery of TGF-β1 with prolonged bioactivity
[21-23]. However, such a physical adsorption-based de-
livery approach requires a high amount of growth factors
and is easily affected by a local microenvironments caus-
ing burst release of the loaded protein. Chemical conju-
gation of growth factors into scaffolds showed a more
prolonged release and significantly reduced initial burse
of the proteins compared to physically absorbed growth
factors [24,25].
In addition, type II collagen (Col II) is known to be
the most abundant protein in the cartilage tissue and to
promote chondrogenic differentiation of MSCs [26,27].
Previous studies demonstrated that TGF-β1-mediated
chondrogenesis was enhanced significantly in the pres-
ence of Col II [28-30]. Chondrocytes bind to Col II
through integrins leading to the formation of signaling
complex that induces chondrogenesis. TGF-β1 interacts
with a receptor complex and transduces its signals
through phosphorylation of the cytoplasmic signaling
molecules (Smads). It has been demonstrated that com-
bination of TGF-β1 and Col II treatment resulted in a
synergistic increase in Smad 2 and 3 phosphorylation
compared with the individual stimulation with TGF-β1
or Col II alone, indicating the signaling cross-talk be-
tween Col II-activated integrin pathway and the TGF-β1
Smad pathway [28-30].
Here, we introduce the sophisticated cartilage tissue
engineering system supplemented with TGF-β1 biocon-
jugation and Col II impregnation into the methacrylated
chitosan (MeGC) hydrogels to promote chondrogenic
differentiation of encapsulated MSCs derived from hu-
man synovium (hSMSCs). We hypothesized that the
TGF-β1 conjugation and Col II impregnation into the
chitosan hydrogels will additively enhance chondrogenicdifferentiation of encapsulated hSMSCs. To test this hy-
pothesis, we encapsulated hSMSCs into the MeGC
hydrogels functionalized with Col II and TGF-β1 and
determined the ability of the hydrogel systems to pro-
mote chondrogenesis using a series of in vitro assays at
different time courses up to 21 days.
Results
Hydrogel fabrication and characterization
Chitosan (MeGC) and Col II-impregnated chitosan
hydrogels (MeGC/Col) were prepared via free radical
polymerization under VBL in the presence of a RF initiator
(Figure 1). TGF-β1 was chemically conjugated into MeGC
prior to hydrogel formation using a Succinimidyl-4-(N-
maleimidomethyl)cyclohexane-1-carboxylate (SMCC) linker
(MeGC/Col/TGF). Cross-sectional SEM images of MeGC/
Col suggested that MeGC hydrogels had fibrous collagen
microstructure homogeneously distributed throughout the
hydrogels (Figure 2B). The conjugation of TGF-β1 onto
MeGC did not alter the microstructure of the cross-linked
hydrogels.
Release of conjugated TGF-β1 from MeGC hydrogels
was measured in a culture medium containing serum.
As expected, the release profiles from the hydrogels
showed a sustained release with a reduced initial burst
and approximate cumulative release of 12% up to 21 days
(Figure 2C). The addition of Col II did not significantly
affect the release kinetics of TGF-β1 from the hydrogel
(Figure 2D). Our previous data showed that approxi-
mately 60% of initially loaded TGF-β1 by an adsorption
method was rapidly released from the hydrogels at day
one in a similar condition (Additional file 1: Figure S1).
Chemically conjugated TGF-β1 was better immobilized
on the hydrogels, thus much less amount of the protein
was released from the delivery system, compared with
weakly adsorbed TGF-β1. SMCC is one of the widely
used crosslinking agents containing an amine-reactive
N-hydroxysuccinimide (NHS) ester and a sulfhydryl-
reactive maleimide group [31]. NHS esters react with
the primary amino groups (−NH2) of MeGC to form
stable amide bonds. Maleimide groups form covalent
crosslinks with sulfhydryl (−SH) moieties on cysteine
residues of TGF-β1 to form stable thioether bonds. A
similar conjugation technique using SMCC was success-
fully employed to immobilize various growth factors, in-
cluding latent TGF-β1, bone morphogenetic protein-2
(BMP-2), and vascular endothelial growth factor (VEGF)
onto biomaterial surfaces, and the conjugated growth
factors maintained their bioactivity [24,32-34]. However,
the conjugation process and chemistry of reaction can
adversely affect the growth factor by protein denatur-
ation and impair the biological function of the growth
factor. Additional studies on protein conformational
changes are needed for the future clinical translation.
Figure 1 Schematic diagram of functionalized MeGC hydrogels. MeGC hydrogels were formed by irradiation of VBL in the presence of RF as a
photoinitiator. MeGC/Col hydrogels were prepared by mixing MeGC solution with Col II followed by photopolymerization. TGF-β1 was bioconjugated
into MeGC via SMCC moiety.
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The bright field microscopic images of encapsulated
hSMSCs cultured in MeGC, MeGC/Col, or MeGC/Col/
TGF hydrogels showed that there was little cell aggrega-
tion at day 1 regardless of the presence of Col II and/or
TGF-β1 (Figure 3A). Cell aggregation was rarely observed
in MeGC hydrogels over the 21-day culture period. In
contrast, MeGC/Col hydrogels appeared to have a few
clusters at day 7 and the area of cell clusters was increased
over time. For TGF-β1 conjugated gels, much bigger cell
clusters were observed after 7 days compared with other
hydrogels. The image analysis data of cell cluster area in
each hydrogel confirmed that there were significantdifferences in cell cluster area between treatment
groups and pure MeGC groups at day 7, 14 and 21 days
(Figure 3B). In particular, there were significant differ-
ences between MeGC/Col and MeGC/Col/TGF hydro-
gels at day 21, indicating that the conjugated TGF-β1
significantly promoted cell aggregations in the hydrogels.
Regarding cellularity of encapsulated hSMSCs, the data re-
vealed that MeGC/Col gels had greatest cellularity as com-
pared to other hydrogels at days 14 and 21. MeGC/Col/
TGF hydrogels had significant increase of cell proliferation,
compared with the MeGC hydrogels (Figure 3C).
The Live/Dead staining images showed that most cells
encapsulated in the all tested hydrogels (>90%) were
Figure 2 Hydrogel characteristics and release kinetics. SEM images of MeGC (A) and MeGC/Col (B) hydrogels. Scale bar = 10 μm. Release
profiles of TGF-β1 from MeGC/TGF (C) and MeGC/Col/TGF (D) hydrogels incubated in culture media with serum.
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differences in cell viability among tested hydrogel
systems, indicating that the use of SMCC, VBL, and
RF all together had no adverse effects on cell viability
(Figure 4).Figure 3 Growth of hSMSCs cultured in hydrogels. (A) Bright field imag
area of cell clusters quantified by image analysis of bright field images. (*: p <
n = 3) (C) Proliferation of hSMSCs in hydrogels measured by CCK assay.Chondrogenic differentiation of encapsulated hSMSCs
To observe in vitro chondrogenic differentiation of encap-
sulated hSMSCs, histology (H&E staining and Safranin-O
staining) and immunohistochemistry (Col II staining) were
performed in this study.es of hSMSCs in the hydrogels. Scale bar = 200 μm. (B) Percentage
0.05 compared with MeGC and #: p < 0.05 compared with MeGC/Col,
Figure 4 Viability of hSMSCs cultured in hydrogels. (A) Live/Dead staining of hSMSCs in the hydrogels and (B) hSMSCs viability (%) from
live/dead image analysis. Scale bar = 200 μm.
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tribution and most of encapsulated cells were round
shape with surrounding lacunae in all tested hydrogels
at day 7, which is the characteristic of chondrogenic dif-
ferentiation (Figure 5). Over the culture period up to day
21, there were no notable differences in cellular activities
in MeGC hydrogels. However, cellular aggregations were
observed in MeGC/Col and MeGC/Col/TGF gels with
more intense cell clusters in TGF-β1-conjugated gels
than MeGC/Col gels.Figure 5 H & E staining of hSMSCs cultured in hydrogels at
days 7, 14, 21 in culture. The encapsulated cells maintained round
cell morphology throughout the culture periods. The cell aggregations
were additively promoted with Col II and TGF-β1 supplementations.
Scale bar = 100 μm.To assess chondrogenic differentiation of encapsulated
hSMSCs, safranin-O staining and Col II immunohisto-
chemistry (IHC) were performed to detect sulfated glycos-
aminoglycan (sGAG) production and Col II deposition
from the encapsulated cells. Increased GAG accumula-
tion was observed over time in MeGC/Col and MeGC/
Col/TGF gels, whereas pure MeGC gels did not show
any differences in Safranin-O staining density over time
(Figure 6A). Quantification of GAG accumulation by
image analysis confirmed that there were significant dif-
ferences between MeGC gels and MeGC/Col/TGF gels
at all time periods and between MeGC/Col gels and
MeGC/Col/TGF gels at day 21 (Figure 6B).
Regarding Col II IHC at day 21, all tested groups
showed positive staining for Col II (Figure 7A). In MeGC
gels, Col II positive staining was observed throughout the
hydrogels but limited inside lacunae, whereas the Col
II staining region was extended into the area surround-
ing the lacunae in MeGC/Col gels. Highly intense posi-
tive Col II staining was found in MeGC/Col/TGF gels
compared with MeGC/Col gels. Quantification of Col
II staining verified these findings that Col II expression
of encapsulated hSMSCs was significantly higher in
MeGC/Col and MeGC/Col/TGF gels at day 21, com-
pared with MeGC gels (Figure 7B).
The cellular activities of encapsulated hSMSCs in MeGC
gels revealed that delivery of TGF-β1 without Col II im-
pregnation in MeGC gels did not show any significant ef-
fects on cellular activities, compared with pure MeGC gels
without TGF-β1 (Additional file 2: Figure S2).
Chondrogenic differentiation of hSMSCs cultured in the
hydrogels was further confirmed by qRT-PCR analysis
(Figure 8). hSMSCs cultured in pellets were used as a
Figure 6 Differentiation of hSMSCs cultured in hydrogels. (A) Safranin-O staining of hSMSCs cultured in hydrogels and (B) quantification of
Safranin-O staining by image analysis. Scale bar = 100 μm. (*: p < 0.05 compared with MeGC and #: p < 0.05 compared with MEGC/Col, n = 3).
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to induce chondrogenesis of MSCs [35-37]. MeGC/Col/
TGF gels significantly increased the expression level of
chondrogenic gene markers Sox 9, aggrecan, and Col II in
hSMSCs, relative to MeGC gels. mRNA level of Col II was
increased 2.5-fold in the MeGC/Col/TGF gels compared
to the MeGC gels, whereas no significant change was ob-
served in the MeGC/Col or MeGC/TGF gels.
Discussion
The primary purpose of this study is to assess whether
Col II nanofiber impregnation and TGF-β1 bioconjuga-
tion into MeGC hydrogels contribute chondrogenic dif-
ferentiation of encapsulated hSMSCs in the gels. TheFigure 7 Differentiation of hSMSCs cultured in hydrogels. (A) Type II collag
quantification of Col II staining by image analysis. Scale bar = 100 μm. (*: p < 0.0results of the current study support the hypothesis that
the Col II impregnation and TGF-β1 conjugation into
the chitosan hydrogels additively promoted chondro-
genic differentiation of the encapsulated hSMSCs.
Although our previous report demonstrated that
MeGC-based hydrogels prepared by VBL and RF,
proven to be biocompatible and to promote ECM pro-
duction (e.g., GAG accumulation) of encapsulated
MSCs, [10] those matrix synthesis may be minimal, thus
the supplementation of exogenous growth factors or
recruiting endogenous ones may be needed to facilitate
chondrogenesis [38,39]. Among soluble biomolecules to
enhance cartilage formation, TGF-β1 was selected in this
study due to its well-known chondrogenic potentialsen staining of hSMSCs cultured in hydrogels at 21 days and (B)
5 compared with MeGC and #: p < 0.05 compared with MeGC/Col, n = 3).
Figure 8 Gene expression of Sox 9, aggrecan, and Collagen type II in hSMSCs cultured in hydrogels or pellets on day 14. (*: p < 0.05
compared with MeGC and #: p < 0.05 compared with MeGC/Col or MeGC/TGF, n = 3).
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hydrogel network to further accelerate chondrogenic dif-
ferentiation since Col II is a main component in the ECM
of articular cartilage [6]. Therefore, in the present study,
sophisticated functional scaffolds with a chemical moiety
(i.e., SMCC) were designed to eventually match unmet
needs for functional cartilage regeneration.
The Col II concentration of 0.4% was optimized in our
previous study to promote chondrogenesis in MeGC
hydrogels [41]. Our previous study showed that the incorp-
oration of Col II (0.4% w/v) increased the compressive
modulus of the hydrogel from 4.6 to 7.0 kPa [41]. We did
not investigate higher concentrations because Col II con-
centrations over 0.4% were too viscous to handle and re-
sulted in non-uniform mixing with MeGC. The final
concentration of 10 μg/ml was chosen for the current stud-
ies because TGF-β1 concentrations above 10 μg/ml re-
duced the mechanical properties of the cross-linked
hydrogel. This may be due to the reduced crosslinking
density or interactions between polymer chains by the con-
jugated proteins. Although the mechanical properties of the
hydrogels were lower than those of native cartilage, our
hydrogel system was designed to mainly serve as an appro-
priate carrier for stem cells and growth factors, and the de-
grading hydrogel will be replaced by nascent cartilage tissue
in vivo with sufficient mechanical support. Additional stud-
ies on the mechanical integrity of the construct in cartilage
defects could further enhance the future clinical translation.
Our release data demonstrated the sustained release of
TGF-β1 chemically conjugated on hydrogel via an
SMCC crosslinker. The observed release may be due to
hydrolysis of covalent linkages in the environment of
serum-supplemented media that present various pro-
teins, electrolytes, hormones, and enzymes. Similar ob-
servations of sustained release have been reported using
BMP-2 conjugated on biomaterial surfaces via SMCC
[24,33]. It is also possible that material surfaces can
affect chemical stability of the conjugates and the releasepattern. It has been demonstrated that different bioma-
terials showed distinctive release pattern of covalently
bound BMP-2 using the same crosslinker [42], indicating
that the substrate material as well as the conjugation
strategy can affect the release pattern. Further studies to
elucidate the conjugation and release mechanisms are
needed to determine appropriate linkage for the TGF-β1
conjugation. Although positively charged TGF-β1 (pI =
9.5) can interact electrostatically with Col II, the
addition of Col II in MeGC hydrogels did not suppress
the release of TGF-β1 from the hydrogels. This is possibly
due to the additional proteins in serum-supplemented
media that abolished the electrostatic interaction effects.
Similar observations of increased release by serum pro-
teins have been reported in our previous study using Col-
coated scaffolds and cationic histone [43]. In contrast,
approximately 70% of the initially loaded TGF-β1 by a
non-specific adsorption method was released from the
MeGC/Col hydrogels during the first week (Additional file
1: Figure S1). We observed a fewer number of cell aggre-
gations in these hydrogels with TGF-β1 adsorption com-
pared with the TGF-β1-conjugated hydrogels, indicating
that the chemical conjugation strategy provides more fa-
vorable microenvironment to induce chondrogenesis.
Similar release kinetics dependent osteogenic activity was
observed in BMP-2 loaded polycaprolactone scaffolds
[33]. Previous studies also revealed that sustained release
of growth factors to the designated sites may further en-
hance cellular responses leading to desired morphogenesis
of progenitor cells [44,45].
While individual use of SMCC, visible blue light (VBL)
and riboflavin (vitamin B2) has proven to be biocompat-
ible [46,47], it is crucial to evaluate the bioactivity of the
integrated system all together. The Live/Dead staining
images and proliferation data revealed that the encapsu-
lated hSMSCs in MeGC-based hydrogels was highly vi-
able throughout the scaffolds (>90%) despite the use of
bioconjugation agent (i.e., SMCC). Furthermore, the
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hSMCSs in MeGC/Col/TGF was lower compared to the
cells in MeGC/Col, suggesting that the conjugated TGF-
β1 on the hydrogels may promote the encapsulated
hSMSCs to undergo chondrogenic differentiation after
14 days of culture. However, hSMSCs encapsulated in
MeGC/TGF hydrogel displayed a similar proliferation
rate to the MeGC group and most of the seeded cells
were present as individual cells without forming aggre-
gation over 21 days, indicating that TGF-β1-mediated
chondrogenesis is not sufficient without collagen inter-
action. Previous studies demonstrated that chondrogenic
differentiation was most predominant in the cells stimu-
lated with TGF-β1 in the presence of Col II, indicating
synergistic effects of Col II binding and TGF-β1 signal-
ing on chondrogenesis [28-30].
It is known that cell-matrix interaction plays import-
ant role in cartilage tissue engineering and previous re-
ports suggest that cell morphology depends on scaffold
type, composition and architecture [48,49]. In cartilage
development, the round cell morphology has to maintain
for chondrogenic differentiation to promote cartilage-
specific ECM production. However, the predominant cell
morphology observed on most scaffolds except for
hydrogels has been known to be elongated fibroblastic
morphology, which triggers cell spreading and fibrous
matrix deposition [50]. Thus, it is not surprising to use
hydrogels for cartilage tissue engineering ranging from
natural hydrogels such as hyaluronic acids to synthetic
ones such as polyethylene (PEG)-based hydrogels [51,52].
However, the cells encapsulated in hydrogels often lose
their chondrogenic phenotype with elongated morph-
ology, depending on hydrogel types and culture conditions
[47,49]. Therefore, it is crucial to design appropriate mi-
croenvironments to promote and maintain chondrogenic
differentiation with round (or spherical) cell morphology
during cell growth [53].
Cell-cell interactions are important steps in mediating
an early mesenchymal condensation and chondrogenesis.
The condensation events are known to be initiated by
cell-cell adhesion mediated by cell adhesion molecules
(N-cadherin, N-CAM) as well as cell-matrix interactions
(collagen, aggrecan) [54-57]. Collagen has been shown
to induce mesenchymal condensation and subsequent
chondrogenesis via integrin-mediated cell adhesion by
enhancing cell-matrix interactions [58-60]. Chondro-
genic differentiation is further modified by the involve-
ment of various growth factors (TGF-β, Wnt, fibroblast
growth factors) that initiate intracellular signaling path-
ways transduced by protein kinase C and mitogen-
activated protein kinases [28,61,62]. One of the most
encouraging findings in the present study is that MeGC
hydrogels supported close cell-cell contact and round
cell morphology maintained throughout the cultureperiods with increased ECM production such as GAG
and Col II expression over time. Moreover, Col II impreg-
nation did not compromise cell morphology despite its fi-
brous nature. It is possible to speculate that cell
morphology of the encapsulated hSMSCs maintained
spherical morphology since their size is greater than that of
collagen fibers [48]. Furthermore, we demonstrated that in-
corporation of Col II and TGF-β1 into the MeGC hydro-
gels at least additively increased density of cell clusters and
cartilage-specific ECM production in the hydrogels. Given
that the Col II initially incorporated in the hydrogel was
obtained from chicken sternal cartilage and the primary
antibody used for IHC has very little cross-reactivity with
chicken, the observed Col II staining indicates cartilaginous
matrix produced by the encapsulated cells, not the Col II
initially added in the hydrogel.
There has been a controversy whether exogenous scaf-
folds are necessary for cartilage development as opposed
to bone regeneration, where a general consensus that ex-
ogenous three dimensional (3D) scaffolds are required
for the tissue development [12,63,64]. However, it is our
point of view and others’ as well that ‘functional’ 3D
scaffolds may be needed for cartilage tissue engineering
to immobilize implanted cells in the defect site and to
facilitate ECM deposition via cell-scaffold interactions
during the tissue development [65]. Overall, MeGC
hydrogels supplemented with Col II impregnation and
TGF-β1 bioconjugation may be an attractive synthetic
ECM for cartilage tissue regeneration.
Conclusions
To enhance chondrogenic differentiation of encapsu-
lated cells, functional chitosan hydrogels were developed
by incorporating TGF-β1 and nanofibrous Col II into
photocrosslinkable MeGC. Controlled delivery of TGF-
β1 with reduced burst release was demonstrated via bio-
conjugation of the protein to the hydrogels. The hydrogel
system did not compromise viability of encapsulated
hSMSCs and the addition of Col II and TGF-β1 promoted
cellular aggregation and chondrogenic differentiation of
the encapsulated cells. This MeGC-based hydrogel system
provides a specific microenvironment tailored to promote
chondrogenesis in the treatment of cartilage defects.
Materials and methods
Materials
Glycol chitosan (GC: molecular weight ~500 kDa), glyc-
idyl methacrylate, riboflavin (RF) sodium salt, and type
II collagen (Col II) purified from chicken sternal cartilage
were all purchased from Sigma-Aldrich (MO, USA) and
used as received. Succinimidyl-4-(N-maleimidomethyl)
cyclohexane-1-carboxylate (SMCC) was purchased from
Pierce (Rockford, IL). Recombinant human TGF-β1 was
obtained from PeproTech (Rocky Hill, NJ). Human
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Orthopedic Surgery).
Preparation of photocrosslinkable hydrogels
Methacrylated glycol chitosan (MeGC) was prepared as
previously reported [10,47]. Briefly, glycidyl Methacrylate
was added to an aqueous solution of 2% (w/v) glycol chi-
tosan (pH 9.0) with 1.1 molar ratio of glycidyl meth-
acrylate to the primary amine groups in chitosan then
proceed to react via gentle shaking at room temperature
for 36 h. The reaction mixture was then neutralized, dia-
lyzed against water for 15 h using membrane with cutoff
molecular weight of 50 kDa, and lyophilized for further
studies. The degree of methacrylation to the GC was
26% as determined via 1H-NMR.
The composite solution of 2% w/v MeGC containing
0.4% w/v Col (MeGC/Col) was prepared by mixing stock
MeGC solution (4% w/v, in PBS) with Col (1.0% w/v, in
0.05% acetic acid). Pure MeGC solution (2% w/v) was
prepared by diluting the 4% w/v MeGC in PBS. The
hydrogel was formed by exposing the solution to visible
blue light (400–500 nm, 500–600 mW/cm2, Bisco Inc.,
Schaumburg, IL) in the presence of RF photoinitiators
(6 μM).
The interior morphology of hydrogels was observed
using scanning electron microscopy (SEM, Nova Nano-
SEM 230, FEI, Hillsboro, OR). The hydrogels were fixed
with 2.5% glutaraldehyde for 2 h at room temperature and
interior morphology was imaged in low vacuum mode.
TGF-β1 conjugation
TGF-β1 was covalently conjugated to MeGC via SMCC
linker. Briefly, 20 μL of SMCC (7.4 mg/mL) was added
to 10 mL of MeGC (2% w/v in PBS) and incubated for
15 h at room temperature with gentle shaking. The reac-
tion mixture was then dialyzed against water and lyophi-
lized to receive MeGC-SMCC. To conjugate TGF-β1 to
MeGC-SMCC, 10 μg of TGF-β1 in PBS was reacted with
2 mL of MeGC-SMCC aqueous solution (1% w/v). Reac-
tion was performed for 15 h under mild shaking at 4°C and
then purified with ultrafiltration tubes (MWCO 100 kDa)
according to the manufacturer’s manual (Millipore). The
concentrated product was recovered, lyophilized, and
stored at −20°C for further study.
To examine the release kinetics of proteins, TGF-β1
tethered hydrogels (MeGC/Col/TGF) containing cells
were prepared as described above and the obtained
hydrogels were incubated in DMEM supplemented with
10% fetal bovine serum (FBS) at 37°C. The final concen-
tration of TGF-β1 in hydrogels was 10 μg/mL. The incu-
bating medium was replaced with fresh medium at the
designated time interval. The amount of released TGF-
β1 in the medium was measured by using an enzyme-
linked immunosorbent assay (ELISA) kit (R&D systems,Minneapolis, MN). Measurements were performed in trip-
licate, and the amount of protein release was expressed as
a percentage of the initial amount of incorporated protein.
Culture of cells in hydrogels
Human SMSCs were expanded in DMEM with 20%
FBS, 100 μg/mL streptomycin, and 100 U/mL penicillin
at 37°C in a 5% CO2 humidified atmosphere. SMSCs
(passage 3–4) were suspended in 40 μl of MeGC,
MeGC/Col, and MeGC/Col/TGF-β1 solutions at a dens-
ity of 10 × 106 cells/mL (final concentration of TGF-β1
was 10 μg/mL). The hydrogels were cultured in chon-
drogenic medium consisting of DMEM with 10% FBS,
ITS+ Premix supplement (BD Biosciences, Bedford,
MA), 100 nM dexamethasone, 40 μg/mL L-proline,
1 mM sodium pyruvate, and 50 μg/mL L-ascorbic acid
2-phosphate (all Sigma-Aldrich) for up to 21 days and
the medium was replaced twice a week.
The growth of SMSCs in the hydrogels was observed
using a light microscope (Olympus IX71, Olympus, Lake
Success, NY). Images of SMSCs in the hydrogels were cap-
tured from three randomly chosen fields. The cluster area
was quantified from captured images using NIH-Image J
software (http:/rsb.info.nih.gov/ij/). Ten to twenty clusters
were counted for each hydrogel sample. Proliferation of
cells was measured using Cell Counting Kit-8 (CCK-8,
Dojindo, Kumamoto, Japan) according to the manufac-
turer’s protocol. To observe the cell viability, cell/hydro-
gels constructs were washed once with PBS and stained
with calcein/ethidium homodimer using a LIVE/DEAD
assay kit (Invitrogen, Carlsbad, CA) at 37°C for 30 min.
Stained samples were observed by a fluorescent micros-
copy (Olympus IX71 microscope). The percentage via-
bility was determined by calculating the number of live
cells (green) normalized to the total number of cells
(green and red). All the experiments were performed in
triplicate (n = 3 per group).
Histological and immunohistochemical analyses
For histological analysis, cultured hydrogels were fixed with
10% neutral buffered formalin, embedded in paraffin, then
sectioned at 5 μm. The sections were deparaffinized then
stained with hematoxylin and eosin (H & E) to examine
cellular distribution and morphology. Safranin-O staining
was performed to assess glycosaminoglycans (GAG)
synthesis. Immunohistochemistry (IHC) was per-
formed to determine Col synthesis. Briefly, sections
were incubated with primary antibody against Col
(anti-human Col; EMD Millipore, Billerica, MA) and
antibody was detected using the SuperPicture™ poly-
mer detection kit with DAB substrate (Invitrogen) per
the manufacturers’ instructions. Images were obtained
using Olympus IX71 microscope. GAG and Col pro-
duction was quantified by image analysis of three
Kim et al. Journal of Biological Engineering 2015, 9:1 Page 10 of 11
http://www.jbioleng.org/content/9/1/1randomly selected fields of each of three Safranin-O
staining or Col IHC samples (n = 9/group) relatively
quantified by using NIH-ImageJ software.
RNA extraction and quantitative real-time polymerase
chain reaction (qRT-PCR)
To investigate the gene expressions of SMSCs in the
hydrogels, SMSCs-laden MeGC, MeGC/Col, MeGC/
TGF, and MeGC/Col/TGF-β1 hydrogels were cultured
in chondrogenic media for 14 days. Total RNA was ex-
tracted using Trizol reagent and RNeasy Mini Plant kit
(Qiagen, Valencia, CA) as previously described [66].
Briefly, 0.5 μg of total RNA was reversely transcribed to
cDNA using a cDNA transcription kit. The expressions
of chondrogenic gene markers Sox 9, aggrecan, and Col
II were measured by quantitative real-time PCR using
LightCycler 480 PCR (Indianapolis, IN) with 20 μl SYBR
Green reaction volume. SMSCs cultured in pellets were
used as a standard of comparison. SMSC pellets were pre-
pared as previously described [36] and cultured in chondro-
genic medium supplemented with 10 ng/mL TGF-β1. The
primers were designed as previously described [67]. The
levels of gene expression were normalized with GAPDH.
The amount of mRNA expression was expressed as a ratio
to the MeGC hydrogel.Statistical analysis
Statistical analysis was performed using one way analysis
of variances (ANOVA) followed by Tukey’s post hoc test.
A value of p < 0.05 was considered statistically significant.Additional files
Additional file 1: Figure S1. Supplementary data of TGF-β1 release
(A) and SMSC growth (B) in MeGC/Col containing non-specifically
adsorbed TGF-β1. Scale bar = 200 μm.
Additional file 2: Figure S2. Supplementary data of SMSC cultured in
MeGC/TGF without collagen at day 21 including (A) Bright field images,
(B) live/dead staining, (C) H & E staining, and (D) Safranin-O staining.
Scale bar = 100 μm.Competing interests
The authors declare that they have no competing interests.Authors’ contributions
JK participated in data interpretation and discussions, and drafted the
manuscript. BL prepared the samples, carried out the experiments, and drafted
the manuscript. SK carried out gene expression and release experiments. BC
carried out sample characterization and release experiments. DE performed cell
isolation and drafted the manuscript. ML conceived and designed the
experiments, and drafted the manuscript. All authors read and approved the
final manuscript.Acknowledgements
This work was supported by the UCLA Academic Senate Research Award
and UCLA School of Dentistry Faculty seed grant.Author details
1Department of Bio and Chemical Engineering, Hongik University, Sejong
339-701, South Korea. 2Division of Advanced Prosthodontics, University of
California, Los Angeles, CA 90095, USA. 3Department of Bioengineering,
University of California, Los Angeles, CA 90095, USA. 4Department of
Orthopaedic Surgery, University of California, Los Angeles, CA 90095, USA.
Received: 3 October 2014 Accepted: 24 December 2014
Published: 14 January 2015References
1. Mehrotra C, Remington PL, Naimi TS, Washington W, Miller R. Trends in
total knee replacement surgeries and implications for public health,
1990–2000. Public Health Rep. 2005;120:278–82.
2. Sasso RC, LeHuec JC, Shaffrey C, Grp SIR. Iliac crest bone graft donor site pain
after anterior lumbar interbody fusion - A prospective patient satisfaction
outcome assessment. J Spinal Disord Tech. 2005;18:S77–81.
3. Sasso RC, LeHuec JC, Shaffrey CI. Iliac crest graft site pain after anterior
lumbar interbody fusion: a prospective patient outcome assessment.
Neurosurgery. 2002;51:581–1.
4. Benya PD, Padilla SR, Nimni ME. Independent regulation of collagen types
by chondrocytes during the loss of differentiated function in culture.
Cell. 1978;15:1313–21.
5. Diaz-Romero J, Gaillard JP, Grogan SP, Nesic D, Trub T, Mainil-Varlet P.
Immunophenotypic analysis of human articular chondrocytes: changes in
surface markers associated with cell expansion in monolayer culture. J Cell
Physiol. 2005;202:731–42.
6. Ahmed TA, Hincke MT. Strategies for articular cartilage lesion repair and
functional restoration. Tissue Eng Part B Rev. 2010;16:305–29.
7. Noth U, Rackwitz L, Heymer A, Weber M, Baumann B, Steinert A, et al.
Chondrogenic differentiation of human mesenchymal stem cells in collagen
type I hydrogels. J Biomed Mater Res A. 2007;83:626–35.
8. Kim IL, Mauck RL, Burdick JA. Hydrogel design for cartilage tissue engineering:
a case study with hyaluronic acid. Biomaterials. 2011;32:8771–82.
9. Noth U, Rackwitz L, Steinert AF, Tuan RS. Cell delivery therapeutics for
musculoskeletal regeneration. Adv Drug Deliver Rev. 2010;62:765–83.
10. Hu J, Hou Y, Park H, Choi B, Hou S, Chung A, et al. Visible light crosslinkable
chitosan hydrogels for tissue engineering. Acta Biomater. 2012;8:1730–8.
11. Park H, Choi B, Hu J, Lee M. Injectable chitosan hyaluronic acid hydrogels
for cartilage tissue engineering. Acta Biomater. 2013;9:4779–86.
12. Huey DJ, Hu JC, Athanasiou KA. Unlike bone, cartilage regeneration remains
elusive. Science. 2012;338:917–21.
13. Natoli RM, Revell CM, Athanasiou KA. Chondroitinase ABC treatment results
in greater tensile properties of self-assembled tissue-engineered articular
cartilage. Tissue Eng Part A. 2009;15:3119–28.
14. Ha CW, Noh MJ, Choi KB, Lee KH. Initial phase I safety of retrovirally transduced
human chondrocytes expressing transforming growth factor-beta-1 in
degenerative arthritis patients. Cytotherapy. 2012;14:247–56.
15. van Lent PL, Blom AB, van der Kraan P, Holthuysen AE, Vitters E, van Rooijen N,
et al. Crucial role of synovial lining macrophages in the promotion of
transforming growth factor beta-mediated osteophyte formation.
Arthritis Rheum. 2004;50:103–11.
16. van Beuningen HM, Glansbeek HL, van der Kraan PM, van den Berg WB.
Differential effects of local application of BMP-2 or TGF-beta 1 on both
articular cartilage composition and osteophyte formation. Osteoarthritis
Cartilage. 1998;6:306–17.
17. McCaffrey TA, Falcone DJ, Vicente D, Du B, Consigli S, Borth W. Protection of
transforming growth factor-beta 1 activity by heparin and fucoidan. J Cell
Physiol. 1994;159:51–9.
18. Lyon M, Rushton G, Gallagher JT. The interaction of the transforming
growth factor-betas with heparin/heparan sulfate is isoform-specific. J Biol
Chem. 1997;272:18000–6.
19. McCaffrey TA, Falcone DJ, Borth W, Weksler BB. Alpha 2-macroglobulin/
transforming growth factor-beta 1 interactions. Modulation by heparin-like
molecules and effects on vascular smooth muscle cells. Ann N Y Acad Sci.
1994;737:368–82.
20. McCaffrey TA, Falcone DJ, Du B. Transforming growth factor-beta 1 is a
heparin-binding protein: identification of putative heparin-binding regions
and isolation of heparins with varying affinity for TGF-beta 1. J Cell Physiol.
1992;152:430–40.
Kim et al. Journal of Biological Engineering 2015, 9:1 Page 11 of 11
http://www.jbioleng.org/content/9/1/121. Park JS, Woo DG, Yang HN, Lim HJ, Chung HM, Park KH. Heparin-bound
transforming growth factor-beta3 enhances neocartilage formation by
rabbit mesenchymal stem cells. Transplantation. 2008;85:589–96.
22. Park JS, Woo DG, Yang HN, Na K, Park KH. Transforming growth factor beta-3
bound with sulfate polysaccharide in synthetic extracellular matrix enhanced
the biological activities for neocartilage formation in vivo. J Biomed Mater Res
A. 2009;91:408–15.
23. Jung HH, Park K, Han DK. Preparation of TGF-beta1-conjugated biodegradable
pluronic F127 hydrogel and its application with adipose-derived stem cells.
J Control Release. 2010;147:84–91.
24. Zhang Q, He QF, Zhang TH, Yu XL, Liu Q, Deng FL. Improvement in the
delivery system of bone morphogenetic protein-2: a new approach to
promote bone formation. Biomed Mater. 2012;7:045002.
25. Bessa PC, Casal M, Reis RL. Bone morphogenetic proteins in tissue
engineering: the road from laboratory to clinic, part II (BMP delivery).
J Tissue Eng Regen Med. 2008;2:81–96.
26. Zhang L, Yuan T, Guo L, Zhang X. An in vitro study of collagen hydrogel to
induce the chondrogenic differentiation of mesenchymal stem cells.
J Biomed Mater Res A. 2012;100:2717–25.
27. Pabbruwe MB, Kafienah W, Tarlton JF, Mistry S, Fox DJ, Hollander AP. Repair
of meniscal cartilage white zone tears using a stem cell/collagen-scaffold
implant. Biomaterials. 2010;31:2583–91.
28. Schneiderbauer MM, Dutton CM, Scully SP. Signaling "cross-talk" between
TGF-beta1 and ECM signals in chondrocytic cells. Cell Signal. 2004;16:1133–40.
29. Bosnakovski D, Mizuno M, Kim G, Takagi S, Okumura M, Fujinaga T.
Chondrogenic differentiation of bovine bone marrow mesenchymal stem
cells (MSCs) in different hydrogels: influence of collagen type II extracellular
matrix on MSC chondrogenesis. Biotechnol Bioeng. 2006;93:1152–63.
30. Warstat K, Meckbach D, Weis-Klemm M, Hack A, Klein G, de Zwart P, et al.
TGF-beta enhances the integrin alpha2beta1-mediated attachment of
mesenchymal stem cells to type I collagen. Stem Cells Dev. 2010;19:645–56.
31. Bieniarz C, Husain M, Barnes G, King CA, Welch CJ. Extended length
heterobifunctional coupling agents for protein conjugations.
Bioconjug Chem. 1996;7:88–95.
32. Lim EH, Sardinha JP, Myers S, Stevens M. Latent transforming growth factor-beta1
functionalised electrospun scaffolds promote human cartilage differentiation:
towards an engineered cartilage construct. Archives of plastic surgery.
2013;40:676–86.
33. Zhang H, Migneco F, Lin CY, Hollister SJ. Chemically-conjugated bone
morphogenetic protein-2 on three-dimensional polycaprolactone scaffolds
stimulates osteogenic activity in bone marrow stromal cells. Tissue Eng Part
A. 2010;16:3441–8.
34. He QF, Zhao YN, Chen B, Xiao ZF, Zhang J, Chen L, et al. Improved cellularization
and angiogenesis using collagen scaffolds chemically conjugated with vascular
endothelial growth factor. Acta Biomater. 2011;7:1084–93.
35. Huang CYC, Reuben PM, D'Ippolito G, Schiller PC, Cheung HS.
Chondrogenesis of human bone marrow-derived mesenchymal stem cells
in agarose culture. Anat Rec Part A. 2004;278A:428–36.
36. Bosnakovski D, Mizuno M, Kim G, Ishiguro T, Okumura M, Iwanaga T, et al.
Chondrogenic differentiation of bovine bone marrow mesenchymal stem
cells in pellet cultural system. Exp Hematol. 2004;32:502–9.
37. Zhang LM, Su PQ, Xu CX, Yang JL, Yu WH, Huang DS. Chondrogenic
differentiation of human mesenchymal stem cells: a comparison between
micromass and pellet culture systems. Biotechnol Lett. 2010;32:1339–46.
38. Cheng NC, Estes BT, Awad HA, Guilak F. Chondrogenic differentiation of
adipose-derived adult stem cells by a porous scaffold derived from native
articular cartilage extracellular matrix. Tissue Eng Part A. 2009;15:231–41.
39. Diekman BO, Rowland CR, Lennon DP, Caplan AI, Guilak F. Chondrogenesis of
adult stem cells from adipose tissue and bone marrow: induction by growth
factors and cartilage-derived matrix. Tissue Eng Pt A. 2010;16:523–33.
40. Chung C, Burdick JA. Engineering cartilage tissue. Adv Drug Deliv Rev.
2008;60:243–62.
41. Choi B, Kim S, Lin B, Wu BM, Lee M. Cartilaginous extracellular matrix-modified
chitosan hydrogels for cartilage tissue engineering. ACS Appl Mater Interfaces.
2014;6:20110–21.
42. Gharibjanian NA, Chua WC, Dhar S, Scholz T, Shibuya TY, Evans GR, et al.
Release kinetics of polymer-bound bone morphogenetic protein-2 and its
effects on the osteogenic expression of MC3T3-E1 osteoprecursor cells. Plast
Reconstr Surg. 2009;123:1169–77.
43. Lee M, Chen TT, Iruela-Arispe ML, Wu BM, Dunn JC. Modulation of protein
delivery from modular polymer scaffolds. Biomaterials. 2007;28:1862–70.44. Lutolf MP, Weber FE, Schmoekel HG, Schense JC, Kohler T, Muller R, et al.
Repair of bone defects using synthetic mimetics of collagenous extracellular
matrices. Nat Biotechnol. 2003;21:513–8.
45. Boerckel JD, Kolambkar YM, Dupont KM, Uhrig BA, Phelps EA, Stevens HY,
et al. Effects of protein dose and delivery system on BMP-mediated bone
regeneration. Biomaterials. 2011;32:5241–51.
46. Ibusuki S, Halbesma GJ, Randolph MA, Redmond RW, Kochevar IE, Gill TJ.
Photochemically cross-linked collagen gels as three-dimensional scaffolds
for tissue engineering. Tissue Eng. 2007;13:1995–2001.
47. Amsden BG, Sukarto A, Knight DK, Shapka SN. Methacrylated glycol chitosan
as a photopolymerizable biomaterial. Biomacromolecules. 2007;8:3758–66.
48. Nuernberger S, Cyran N, Albrecht C, Redl H, Vecsei V, Marlovits S. The influence
of scaffold architecture on chondrocyte distribution and behavior in matrix-
associated chondrocyte transplantation grafts. Biomaterials. 2011;32:1032–40.
49. Awad HA, Wickham MQ, Leddy HA, Gimble JM, Guilak F. Chondrogenic
differentiation of adipose-derived adult stem cells in agarose, alginate, and
gelatin scaffolds. Biomaterials. 2004;25:3211–22.
50. Dehne T, Karlsson C, Ringe J, Sittinger M, Lindahl A. Chondrogenic
differentiation potential of osteoarthritic chondrocytes and their possible
use in matrix-associated autologous chondrocyte transplantation.
Arthritis Res Ther. 2009;11:R133.
51. Toh WS, Lee EH, Guo XM, Chan JKY, Yeow CH, Choo AB, et al. Cartilage
repair using hyaluronan hydrogel-encapsulated human embryonic stem
cell-derived chondrogenic cells. Biomaterials. 2010;31:6968–80.
52. Hoffman AS. Hydrogels for biomedical applications. Adv Drug Deliver Rev.
2002;54:3–12.
53. Hutmacher DW. Scaffolds in tissue engineering bone and cartilage.
Biomaterials. 2000;21:2529–43.
54. Cushing MC, Anseth KS. Materials science. Hydrogel cell cultures. Science.
2007;316:1133–4.
55. DeLise AM, Fischer L, Tuan RS. Cellular interactions and signaling in cartilage
development. Osteoarthritis and cartilage/OARS, Osteoarthritis Research
Society. 2000;8:309–34.
56. Tacchetti C, Tavella S, Dozin B, Quarto R, Robino G, Cancedda R. Cell
condensation in chondrogenic differentiation. Exp Cell Res. 1992;200:26–33.
57. Hall BK, Miyake T. All for one and one for all: condensations and the
initiation of skeletal development. Bioessays. 2000;22:138–47.
58. Lu ZF, Doulabi BZ, Wuisman PI, Bank RA, Helder MN. Influence of collagen
type II and nucleus pulposus cells on aggregation and differentiation of
adipose tissue-derived stem cells. J Cell Mol Med. 2008;12:2812–22.
59. Jurgens WJ, Lu Z, Zandieh-Doulabi B, Kuik DJ, Ritt MJ, Helder MN.
Hyperosmolarity and hypoxia induce chondrogenesis of adipose-derived stem
cells in a collagen type 2 hydrogel. J Tissue Eng Regen Med. 2012;6:570–8.
60. Yu SM, Li Y, Kim D. Collagen mimetic peptides: progress towards functional
applications. Soft Matter. 2011;7:7927–38.
61. Chun JS, Oh H, Yang S, Park M. Wnt signaling in cartilage development and
degeneration. BMB Rep. 2008;41:485–94.
62. Yang G, Yang X. Roles of TGF-b superfamily in the genesis, development
and maintenance of cartilage. Yi chuan = Hereditas/Zhongguo yi chuan xue
hui bian ji. 2008;30:953–9.
63. Schubert T, Anders S, Neumann E, Scholmerich J, Hofstadter F, Grifka J, et al.
Long-term effects of chondrospheres on cartilage lesions in an autologous
chondrocyte implantation model as investigated in the SCID mouse model.
Int J Mol Med. 2009;23:455–60.
64. Lewis PB, McCarty 3rd LP, Yao JQ, Williams JM, Kang R, Cole BJ. Fixation of
tissue-engineered human neocartilage constructs with human fibrin in a
caprine model. J Knee Surg. 2009;22:196–204.
65. Chung C, Burdick JA. Influence of three-dimensional hyaluronic acid
microenvironments on mesenchymal stem cell chondrogenesis.
Tissue Eng Part A. 2009;15:243–54.
66. Fan JB, Park H, Tan S, Lee M. Enhanced osteogenesis of adipose derived
stem cells with noggin suppression and delivery of BMP-2. Plos One.
2013;8:e72474.
67. Liu SQ, Tian QA, Hedrick JL, Hui JHP, Ee PLR, Yang YY. Biomimetic hydrogels
for chondrogenic differentiation of human mesenchymal stem cells to
neocartilage. Biomaterials. 2010;31:7298–307.
doi:10.1186/1754-1611-9-1
Cite this article as: Kim et al.: TGF-β1 conjugated chitosan collagen
hydrogels induce chondrogenic differentiation of human synovium-derived
stem cells. Journal of Biological Engineering 2015 9:1.
